Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

被引:34
|
作者
Hong, Ying [1 ]
Rohatagi, Shashank [2 ]
Habtemariam, Bahru [1 ]
Walker, Joseph R. [2 ]
Schwartz, Sherwyn L. [3 ]
Mager, Donald E. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[3] Diabetes & Glandular Dis Clin, San Antonio, TX USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 06期
关键词
type 2 diabetes mellitus; metformin; pharmacokinetics; pharmacodynamics; mathematical modeling;
D O I
10.1177/0091270008316884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The exposure-response properties of metformin were characterized in 12 subjects with type 2 diabetes mellitus. The time course of drug concentration and effects on fasting plasma glucose and lactic acid concentrations were used from a study in which subjects received 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days. Pharmacokinetic sampling included morning trough concentrations obtained on days 7 to 9 and rich sampling (15 time points) on day 10. Fasting plasma glucose and lactic acid concentrations were measured on days 0 to 10 and served as biomarkers of therapeutic effect and tolerability, respectively. A population pharmacokinetic/pharmacodynamic analysis was conducted using nonlinear mixed effects modeling. Metformin pharmacokinetics were described using a 1-compartment model with first-order absorption. Population mean estimates (relative standard error [RSE]) of clearance (CLIF) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively. Covariate analyses revealed that creatinine clearance (CLCR) significantly influenced metformin CLIF [CL/F = 79.0.(CLCR/80)(0.822)]. An indirect response model was applied to describe the antihyperglycemic effect of metformin. Population mean estimates (RSE) of baseline fasting plasma glucose and the drug concentration producing half-maximal effect were 241 mg.dL(-1) (4.6%) and 4.23 mg.L-1 (31.0%). An empirical linear model was used to describe a slight progressive increase in fasting lactic acid during metformin treatment with an estimated slope coefficient (RSE) of 0.0005 mM.mL.ng(-1) (38.1 %). Model evaluation by predictive check and non-parametric bootstrap analysis suggested that the proposed model is robust, and parameter values were estimated with good precision. Simulations suggested that the clinical utility of metformin was maintained over the dose range evaluated with respect to fasting plasma glucose and lactic acid response.
引用
收藏
页码:696 / 707
页数:12
相关论文
共 50 条
  • [31] Contraindications to metformin therapy among patients with type 2 diabetes mellitus
    Sweileh, Waleed M.
    PHARMACY WORLD & SCIENCE, 2007, 29 (06): : 587 - 592
  • [32] Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
    Hoeben, Eef
    De Winter, Willem
    Neyens, Martine
    Devineni, Damayanthi
    Vermeulen, An
    Dunne, Adrian
    CLINICAL PHARMACOKINETICS, 2016, 55 (02) : 209 - 223
  • [33] Population pharmacokinetics and exposure-response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
    Kuchimanchi, Mita
    Grover, Anita
    Emery, Maurice G.
    Somaratne, Ransi
    Wasserman, Scott M.
    Gibbs, John P.
    Doshi, Sameer
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 (03) : 505 - 522
  • [34] Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus
    Eef Hoeben
    Willem De Winter
    Martine Neyens
    Damayanthi Devineni
    An Vermeulen
    Adrian Dunne
    Clinical Pharmacokinetics, 2016, 55 : 209 - 223
  • [35] Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus
    Busse, David
    Tang, Weifeng
    Scheerer, Markus
    Danne, Thomas
    Biester, Torben
    Sokolov, Viktor
    Boulton, David
    Parkinson, Joanna
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (08) : 1820 - 1828
  • [36] EFFECT OF GENETICPOLYMORPHISM OF OCT AND MATE TRANSPORTERS ON METFORMIN RESPONSE IN KOREAN TYPE 2 DIABETES MELLITUS PATIENTS
    Park, Jeong-eun
    Choi, Jee-hye
    Kim, Tae-eun
    Kwon, Hyeog-jung
    Shin, Kwang-Hee
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S86 - S86
  • [37] Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus
    Nasykhova, Yulia A.
    Barbitoff, Yury A.
    Tonyan, Ziravard N.
    Danilova, Maria M.
    Nevzorov, Ivan A.
    Komandresova, Tatiana M.
    Mikhailova, Anastasiia A.
    Vasilieva, Tatiana V.
    Glavnova, Olga B.
    Yarmolinskaya, Maria, I
    Sluchanko, Evgenia, I
    Glotov, Andrey S.
    GENES, 2022, 13 (08)
  • [38] A Pharmacometabolomic Approach to Predict Response to Metformin in Early-Phase Type 2 Diabetes Mellitus Patients
    Park, Jeong-Eun
    Jeong, Gui-Hwa
    Lee, In-Kyu
    Yoon, Young-Ran
    Liu, Kwang-Hyeon
    Gu, Namyi
    Shin, Kwang-Hee
    MOLECULES, 2018, 23 (07):
  • [39] Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea
    Rachman, Abu
    Sauriasari, Rani
    Syafhan, Nadia Farhanah
    Prawiroharjo, Pukovisa
    Risni, Hindun Wilda
    KESMAS-NATIONAL PUBLIC HEALTH JOURNAL, 2022, 17 (04): : 270 - 278
  • [40] DIABETES Preventing type 2 diabetes mellitus: is metformin the answer?
    Buchanan, Thomas A.
    Xiang, Anny H.
    NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (05) : 253 - 254